FDA approves Eli Lilly’s Trulicity to reduce cardiovascular risks in type 2 diabetic patients

FILE PHOTO: Boxes of the drug trulicity, made by Eli Lilly and Company, sit on a counter at a pharmacy in Provo, Utah, U.S. January 9, 2020. REUTERS/George Frey/File Photo

(Reuters) – Eli Lilly and Co said on Friday the U.S. Food and Drug Administration has approved Trulicity for reducing cardiovascular risk factors in type 2 diabetic patients.

The approval makes Trulicity the first and only type 2 diabetes drug approved to reduce heart related risks in adults with and without established cardiovascular disease, the company said in a statement.

Reporting by Maria Ponnezhath in Bengaluru

Leave a Reply